Bod Australia reports first prescriptions in the UK

Latest News

Medicinal cannabis company Bod Australia (ASX:BDA) says it has received its first prescriptions for MediCabilis from patients in the UK.

The company said the prescriptions were received from a medicinal cannabis organisation with a number of clinics across the UK. 

Bod described the UK as a "major market opportunity" with approximately 7.3 million consumers using medicinal cannabis annually. It said it expects prescription volumes to increase materially in the coming months particularly with the introduction of its 2.5 per cent and 10 per cent strength products.

According to CEO Jo Patterson, “Securing the first international prescriptions for MediCabilis has been months in the making and it is the critical catalyst for a rapid increase in prescription volumes in the United Kingdom.

“Our UK market entry has included rigorous patient and physician education initiatives, as well as collaborative work with our distribution partners to ensure we have the necessary infrastructure in place to scale operations rapidly. This is not quickly or easily replicated, so we have an immediate market advantage here.

“Bod is now actively engaging with physicians and medical organisations across the UK in a bid to further educate them about the MediCabilis™ range. We are encouraged by the response we are receiving and growing patient demand underpins our confidence that this will be a major growth market for MediCabilis.

“The UK is spearheading Bod’s international expansion efforts and will act as the springboard into Europe. We have a large number of growth initiatives underway, including new market entries and product introductions. We look forward to communicating our successes.”